ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Rating of “Buy” by Brokerages
Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have been given an average recommendation of “Buy” by the six ratings firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month […]
Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have been given an average recommendation of “Buy” by the six ratings firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month […]
